rebel Financial rebel Financial
← All Posts
SMTI

Sanara MedTech Inc.

October 01, 2026 • Author: Phil Ratcliff • SMTI
Item Proposal Vote
1 A proposal to approve and adopt the Agreement and Plan of Merger, dated as of July 29, 2026 (as it has been and may be amended, supplemented, waived or otherwise modified in accordance with its terms, the "Merger Agreement"), by and among MiMedx Group, Inc., a Florida corporation ("MiMedx"), Sanara MedTech Inc., a Texas corporation ("Sanara") and Mustang Merger Sub, Inc., a wholly-owned subsidiary of MiMedx ("Merger Sub"), pursuant to which, among other things, Merger Sub will merge with and into Sanara, with Sanara surviving as a wholly-owned subsidiary of MiMedx (the "Merger"), and approve the consummation of the transactions contemplated by the Merger Agreement, including the Merger (such proposal, the "Merger Proposal"). ✓ For
2 A proposal to approve, on a non-binding, advisory basis, the compensation that may be paid or become payable to Sanara’s named executive officers that is based on or otherwise relates to the Merger (the "Advisory Compensation Proposal"). ✓ For
3 A proposal to approve one or more adjournments of the special meeting of Shareholders of Sanara (such meeting, including any adjournments or postponements thereof, the "Special Meeting"), if necessary, to solicit additional proxies if there are not sufficient votes cast at the Special Meeting to approve the Merger Proposal (the "Adjournment Proposal"). ✓ For
Attachments
📄
SMTI_Proxy_Statement_09152026.pdf 1.6 MB
This article was written for information purposes only and its content should not be construed by any consumer and/or prospective client as rebel Financial's solicitation to affect, or attempt to affect transactions in securities, or the rendering of personalized investment advice for compensation. No client or prospective client should assume that any such discussion serves as the receipt of, or a substitute for, personalized advice from rebel Financial, or from any other investment professional. See our disclosures page for more information.